Novel targets in solid tumors: MEK inhibitors

Clinical Advances in Hematology and Oncology

Volumn 4, Issue 11, 2006, Pages 831-836

  Messersmith, Wells A ^a   Hidalgo, Manuel ^b   Carducci, Michael ^b   Eckhardt, S Gail ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

ERK; MAPK; MEK inhibitor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; ARRY 142886; AZD 6244; B RAF KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PD 184362; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TAMOXIFEN;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; CANCER CELL CULTURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; EDEMA; FACE EDEMA; FATIGUE; FOOD DRUG INTERACTION; HUMAN; HYPOXIA; LIPID DIET; LIVER FUNCTION TEST; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PANCREAS CANCER; PATIENT SELECTION; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SYNCOPE; TASTE; TASTE DISORDER; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL DISORDER;

ANTINEOPLASTIC AGENTS; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 33845353775     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Sebolt-Leopold JS. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr Pharm Des. 2004;10:1907-1914.
2. Seger R, Krebs EG. The MAPK signaling cascade. Faseb J. 1995;9:726-735.
3. McCormick F. Signal transduction. How receptors turn Ras on. Nature. 1993; 363:15-16.
4. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11-22
5. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6:313-319
6. Maemura M, Iino Y, Koibuchi Y, Yokoe T, Morishita Y. Mitogen-activated protein kinase cascade in breast cancer. Oncology. 1999;57(suppl 2):37-44.
7. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients Int J Cancer. 2000;89:384-388.
8. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest. 1997;99:1478-1483.
9. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813-822
10. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 1994;77:841-852.
11. Minster SJ, Matten WT, Hermann AS, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science. 1994;265:966-970.
12. Brott BK, Alessandrini A, Largaespada DA, et al. MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth Differ. 1993;4:921-929.
13. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004;11:1192-1197.
14. Seger R, Ahn NG, Posada J, et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 1992;267:14373-14381.
15. Zheng CF, Guan KL. Cloning and characterization of two distinct human extra-cellular signal-regulated kinase activator kinases, MEK1 and MEK2. J Biol Chem. 1993;268:11435-11439
16. Giroux S, Tremblay M, Bernard D, et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol 1999;9:369-372.
17. Belanger LF, Roy S, Tremblay M, et al. Mek2 is dispensable for mouse growth and development. Mol Cell Biol. 2003;23:4778-4787.
18. Scholl FA, Dumesic PA, Khavari PA. Effects of active MEK1 expression in vivo. Cancer Lett 2005;230:1-5.
19. Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem. 2005;5:215-229
20. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-27494.
21. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 1995;92: 7686-7689.
22. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351(pt 1):95-105.
23. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623-18632.
24. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. Oct 2003;30 (5 suppl 16):105-116.
25. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281-5293.
26. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456-4462.
27. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4:937-947.
28. Lorusso PM, Krishnamurthy S, Rinehart J, et al A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. J Clin Oncol. 2005;23(16S):3011.
29. Menon SS, Whitfield LR, Sadis SS, et al. Pharmacokinetics (PK) and pharmaco-dynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. J Clin Oncol. 2005;23(16S):3066.
30. Wallace EM, Lyssikatos J, Blake JF, et al. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones. J Med Chem. 2006;49:441-444.
31. Chow L, Eckhardt SG, Reid J, et al, A first in human dose-ranging study to assess the pharmacokinetics, pharmacodynamics, and toxicities of the MEK inhibitor, ARRY-142886 (AZD6244) in patients with advanced solid malignancies. Proc AACR-EORTC-NCI Targeted Ther Conference. 2005:C162.
32. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439:358-362.
33. Normanno N, De Luca A, Maiello MR, et al. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006;207:420-427.
34. Djahansouzi S, Heimerzheim T, Reinhardt M, et al. Therapeutic doses of Tamoxifen only partially inhibit the non-genomic effects of Estrogen: Evidence for additive antiproliferative effect of Tamoxifen with MEK inhibitor. J Clin Oncol. 2005;23(16S):3195.
35. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006;5:1136-1144.
36. Legrier ME DSS, Yan HG, et al, Chemosensitization by dual pharmacological inhibition of MEK and MTRO signaling pathways in human non-small cell lung cancer (NSCLC). Proc Amer Assoc Can Res. 2006: Abstract 4867.
37. McDaid HM, Lopez-Barcons L, Grossman A, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005;65:2854-2860.
38. Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br J Cancer. 2004;90:1076-1083
39. Sengupta S, Sellers LA, Li RC, et al. Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation. 2003;107:2955-2961.
40. Tran E SK, Chow P, and Huynh H, Targeted inhibition of the MEK-ERK signaling cascade by the selective MEK1/2 inhibitor AZD6244 (ARRY-142886) for the treatment of hepatocellular carcinoma. Amer Assoc Can Res. 2006: Abstract 5470.
41. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001; 108:851-859.
42. Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61:5106-5115
43. Yu C, Krystal G, Varticovksi L, et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res. 2002;62:188-199.
44. Stadler WM, Rosner G, Small E, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma - CALGB 69901. J Clin Oncol. 2005;23:3726-3732